General Information of Drug (ID: DM3H2U4)

Drug Name
Patrome Drug Info
Indication
Disease Entry ICD 11 Status REF
Parkinson disease 8A00.0 Phase 3 [1]
Cross-matching ID
TTD Drug ID
DM3H2U4

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Vitamin B6 DMDBZMV Vitamin B6 deficiency 5B5D Approved [3]
Carbidopa DMHRG8Q Parkinson disease 8A00.0 Approved [4]
Benserazide DMLU8NX N. A. N. A. Phase 3 [4]
AV-201 DMDL9WU Parkinson disease 8A00.0 Phase 2 [5]
VY-AADC DMPSBTL Parkinson disease 8A00.0 Phase 2 [6]
GT-AADC DM8N3OQ Aromatic L-amino acid decarboxylase deficiency 5C59.00 Phase 2 [7]
PTC-AADC DM9ZHE3 Aromatic L-amino acid decarboxylase deficiency 5C59.00 Phase 2 [8]
ProSavin DMJ42E6 Parkinson disease 8A00.0 Phase 1/2 [9]
OXB-102 DMXF9DM Parkinson disease 8A00.0 Phase 1/2 [10]
VY-AADC01 DM0N71R Parkinson disease 8A00.0 Phase 1 [11]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Aromatic-L-amino-acid decarboxylase (DDC) TTN451K DDC_HUMAN Modulator [2]

References

1 Dopamine dysregulation syndrome, addiction and behavioral changes in Parkinson's disease. Parkinsonism Relat Disord. 2008;14(4):273-80.
2 The aromatic-L-amino acid decarboxylase inhibitor carbidopa is selectively cytotoxic to human pulmonary carcinoid and small cell lung carcinoma cells. Clin Cancer Res. 2000 Nov;6(11):4365-72.
3 Functional COMT variant predicts response to high dose pyridoxine in Parkinson's disease. Am J Med Genet B Neuropsychiatr Genet. 2005 Aug 5;137B(1):1-4.
4 Catechol-O-methyltransferase inhibitors in the management of Parkinson's disease. Semin Neurol. 2001;21(1):15-22.
5 UCSF report
6 Clinical pipeline report, company report or official report of Voyager Therapeutics.
7 Clinical pipeline report, company report or official report of PTC Therapeutics.
8 ClinicalTrials.gov (NCT04903288) An Open-Label Trial to Address the Safety of the SmartFlow MR-Compatible Ventricular Cannula for Administering Eladocagene Exuparvovec to Pediatric Subjects. U.S.National Institutes of Health.
9 Clinical pipeline report, company report or official report of Oxford BioMedica.
10 Clinical pipeline report, company report or official report of Oxford BioMedica.
11 Safety of AADC Gene Therapy for Moderately Advanced Parkinson Disease: Three-Year Outcomes From the PD-1101 Trial. Neurology. 2022 Jan 4;98(1):e40-e50.